Cancer Res Treat.  2019 Apr;51(2):611-622. 10.4143/crt.2018.191.

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Affiliations
  • 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wskimsmc@skku.edu
  • 2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

PURPOSE
Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy of pembrolizumab in NHL patients are limited.
MATERIALS AND METHODS
We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)"’positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression.
RESULTS
Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%).
CONCLUSION
Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.

Keyword

Lymphoma; Pembrolizumab; PDL1; Epstein-Barr virus

MeSH Terms

Cell Death
Epstein-Barr Virus Infections
Herpesvirus 4, Human
Humans
Lymphoma
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin*
Salvage Therapy
T-Lymphocytes

Figure

  • Fig. 1. Clinical outcome and treatment cycles of NK/T-cell lymphoma (NKTCL), primary mediastinal B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), and T-lymphoblastic lymphoma (T-LBL). EBV, Epstein-Barr virus; PDL1, programmed cell death ligand 1; H, high; CR, complete response; NA, not available; L, low; PR, partial response; PD, progressive disease.

  • Fig. 2. (A) Comparison of programmed cell death ligand 1 (PDL1) expression in 76 patients with non-Hodgkin lymphoma shows different frequencies of high (≥ 50% of PDL1-positive tumor cells), low (1%-49% of PDL1-positive tumor cells), and no expression. High PDL1 expression is more frequent in NK/T-cell lymphoma (NKTCL; 15/28, 54%) and primary mediastinal B-cell lymphoma (PMBCL; 4/6, 67%) than in peripheral T-cell lymphoma (PTCL; 2/7, 28%), diffuse large B-cell lymphoma (DLBCL; 2/18, 11%), and T-lymphoblastic lymphoma (T-LBL; 0/8, 0%). No case of PDL1 high expression is observed in primary central nervous system diffuse large B-cell lymphoma (CNS DLBCL; 0/3), mantle cell lymphoma (MCL, 0/2), or enteropathy-associated T-cell lymphoma (EATL; 0/1). However, subcutaneous panniculitis-like T-cell lymphoma (SPTCL; 2/2) and angioimmunoblastic T-cell lymphoma (AITL; 1/1) show high PDL1 expression. (B) Epstein-Barr virus (EBV)–positive non-Hodgkin lymphoma (NHL) shows a significantly higher proportion of high PDL1 expression (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001).

  • Fig. 3. (A) Immunohistochemistry for programmed cell death ligand 1 (PDL1) shows ≥ 50% of tumor cells positively stained (brown membranous staining) in a case of extranodal NK/T-cell lymphoma (top left); decrease in blood Epstein-Barr virus (EBV) DNA level after pembrolizumab treatment (top right); decrease in fluorodeoxyglucose (FDG) uptake in liver and spleen after pembrolizumab treatment (bottom). (B) Immunohistochemistry for PDL1 shows < 1% of tumor cells positively stained in a case of extranodal NK/T-cell lymphoma (top left); increase in blood EBV DNA level even after pembrolizumab treatment (top right); increase in the extent and intensity of FDG uptake in a soft tissue mass in an extremity after pembrolizumab treatment (bottom).


Reference

References

1. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31:1970–6.
Article
2. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130:1800–8.
Article
3. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010; 37:430–9.
Article
4. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13:227–42.
Article
5. Kwong YL, Chan TS, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017; 129:2437–42.
Article
6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32:3059–68.
Article
7. Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015; 2:e66–74.
8. Dako North America. PD-L1 IHC 22C3 pharmDx (package insert). Carpinteria, CA: Dako North America;2015.
9. Lai J, Xu P, Jiang X, Zhou S, Liu A. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer. 2017; 17:507.
Article
10. Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016; 95:1913–5.
Article
11. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017; 130:267–70.
Article
12. Nastoupil LJ, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, et al. High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. Hematol Oncol. 2017; 35(Suppl 2):120–1.
Article
13. Chan TS, Khong PL, Kwong YL. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Ann Hematol. 2016; 95:1917–8.
Article
14. Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016; 54:17–24.
Article
15. Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, et al. PD-L1 status in refractory lymphomas. PLoS One. 2016; 11:e0166266.
Article
16. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015; 126:2193–201.
Article
17. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34:2690–7.
Article
18. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123:2062–5.
Article
19. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127:869–81.
Article
20. Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, et al. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. 2017; 35:487–96.
Article
21. Jo JC, Kim M, Choi Y, Kim HJ, Kim JE, Chae SW, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2017; 96:25–31.
Article
22. Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016; 469:581–90.
Article
23. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017; 129:3419–27.
Article
24. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19:3462–73.
Article
25. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016; 24:392–7.
Article
26. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375:1823–33.
Article
27. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016; 128:2489–96.
Article
28. Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol. 2017; 96:647–51.
Article
29. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34:3733–9.
Article
30. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35:2125–32.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr